131 related articles for article (PubMed ID: 31707444)
1. PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity.
Fontaine SD; Santi AD; Reid R; Smith PC; Ashley GW; Santi DV
Cancer Chemother Pharmacol; 2020 Jan; 85(1):225-229. PubMed ID: 31707444
[TBL] [Abstract][Full Text] [Related]
2. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Mallick P; Shah P; Gandhi A; Ghose R
Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
[TBL] [Abstract][Full Text] [Related]
3. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
4. Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1
Qin Y; Wang N; Chen F; Han X; Zhu Y; Rang Y; Zhai X; Lu Y
Pharmazie; 2020 May; 75(5):186-190. PubMed ID: 32393425
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
Iwase M; Fujita KI; Nishimura Y; Seba N; Masuo Y; Ishida H; Kato Y; Kiuchi Y
Cancer Chemother Pharmacol; 2019 May; 83(5):993-998. PubMed ID: 30810774
[TBL] [Abstract][Full Text] [Related]
9. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
[TBL] [Abstract][Full Text] [Related]
10. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
Gagné JF; Montminy V; Belanger P; Journault K; Gaucher G; Guillemette C
Mol Pharmacol; 2002 Sep; 62(3):608-17. PubMed ID: 12181437
[TBL] [Abstract][Full Text] [Related]
11. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
Tallman MN; Miles KK; Kessler FK; Nielsen JN; Tian X; Ritter JK; Smith PC
J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228
[TBL] [Abstract][Full Text] [Related]
12. Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft.
Fontaine SD; Hann B; Reid R; Ashley GW; Santi DV
Cancer Chemother Pharmacol; 2019 Oct; 84(4):729-738. PubMed ID: 31321449
[TBL] [Abstract][Full Text] [Related]
13. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
[TBL] [Abstract][Full Text] [Related]
14. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Prijovich ZM; Chen KC; Roffler SR
Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
[TBL] [Abstract][Full Text] [Related]
15. Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.
Kato A; Ueyama J; Abe F; Hotta K; Tsukiyama I; Oshima T; Kondo F; Saito H; Hasegawa T
Anticancer Res; 2011 Sep; 31(9):2915-22. PubMed ID: 21868538
[TBL] [Abstract][Full Text] [Related]
16. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
Yong WP; Ramirez J; Innocenti F; Ratain MJ
Clin Cancer Res; 2005 Sep; 11(18):6699-704. PubMed ID: 16166450
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
[TBL] [Abstract][Full Text] [Related]
18. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
[TBL] [Abstract][Full Text] [Related]
19. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
Gupta E; Wang X; Ramirez J; Ratain MJ
Cancer Chemother Pharmacol; 1997; 39(5):440-4. PubMed ID: 9054958
[TBL] [Abstract][Full Text] [Related]
20. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
Nozawa T; Minami H; Sugiura S; Tsuji A; Tamai I
Drug Metab Dispos; 2005 Mar; 33(3):434-9. PubMed ID: 15608127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
